Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment

• Published in: Journal of allergy and clinical immunology Vol. 122; no. 5; pp. 992 - 1000
• Main Authors: Murata, Junko, Abe, Riichiro, Shimizu, Hiroshi
• Format: Journal Article
• Language: English
• Published: New York, NY Mosby, Inc 01.11.2008; Elsevier; Elsevier Limited
• Subjects: Adolescent; Adult; Age; Aged; Aged, 80 and over; Allergy and Immunology; Apoptosis; Biological and medical sciences; Biomarkers - blood; Child; Cytokines; Fas Ligand Protein - blood; Fas Ligand Protein - immunology; Female; Fundamental and applied biological sciences. Psychology; Fundamental immunology; Humans; Ligands; Male; Medical sciences; Middle Aged; Mortality; Mucous Membrane - immunology; Pathogenesis; Predictive Value of Tests; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis; Skin; Skin - immunology; Soluble Fas ligand; Stevens-Johnson syndrome; Stevens-Johnson Syndrome - immunology; toxic epidermal necrolysis; Womens health; Young Adult; Stevens-Johnson syndrome; sCD40L; FasL; ND; ODSRs; EM; Soluble Fas ligand; TEN; SJS; MPR; toxic epidermal necrolysis; Fas ligand; Ordinary types of drug-induced skin reactions; Soluble CD40 ligand; Not detectable; Maculopapular rash; Erythema multiforme; Bullous dermatosis; Human; Immunopathology; Skin disease; Erythroderma; Stomatology; Cytokine; Soluble form; Eye disease; Immunology; Tumor necrosis factor; Skin; Lyell syndrome
• ISSN: 0091-6749; 1097-6825; 1097-6825
• DOI: 10.1016/j.jaci.2008.06.013

It is difficult to distinguish the early phase of Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) from other ordinary types of drug-induced skin reactions (ODSRs). Levels of several serum soluble factors, including soluble Fas ligand (sFasL), have been reported to be increased in patients with SJS/TEN; however, the marker to predict the onset of SJS/TEN before the development of skin detachment or mucosal lesions has not been identified. We sought to determine whether sFasL might be a useful marker in the early stages of SJS/TEN. Sera of 19 patients with SJS and 16 patients with TEN at 1 or multiple time points were obtained from Japanese multiple hospitals. The disease onset (day 1) was defined when erosion/ulceration of the mucocutaneous or ocular lesion first developed. For the investigation of soluble factors, including sFasL, TNF-α, IFN-γ, IL-6, and sCD40 ligand, we used ELISAs and Cytometric Bead Arrays. Before disease onset (day −4 to approximately −2), 7 samples were available, and we detected the highest concentrations of sFasL in 5 (71.4%) of 7 patients. Increased sFasL levels decreased rapidly within 5 days of disease onset. In all 32 patients with ODSRs and 33 healthy control subjects, no increase of sFasL levels was detected. Other soluble factor concentrations did not show significant difference with those seen in patients with SJS/TEN before disease onset and ODSRs. The sFasL levels of sera in patients with SJS/TEN are significantly increased before development of skin detachment, mucosal lesions, or both.